We serve Chemical Name:4-Fluoro-2-methylpyridine CAS:766-16-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Fluoro-2-methylpyridine
CAS.NO:766-16-5
Synonyms:Pyridine, 4-fluoro-2-methyl-;4-Fluoro-2-methylpyridine
Molecular Formula:C6H6FN
Molecular Weight:111.117
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:130.3±20.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.477
PSA:12.89000
Exact Mass:111.048424
LogP:1.14
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Pyridine, 4-fluoro-2-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluoro-2-methylpyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyridine, 4-fluoro-2-methyl- Use and application,Pyridine, 4-fluoro-2-methyl- technical grade,usp/ep/jp grade.
Related News: The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen��s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination. 4-Fluoro-2-methylpyridine manufacturer A system that allows Chinese citizens to enter South Korea��s Jeju Island without a visa is to be temporarily suspended. 4-Fluoro-2-methylpyridine supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 4-Fluoro-2-methylpyridine vendor A system that allows Chinese citizens to enter South Korea��s Jeju Island without a visa is to be temporarily suspended. 4-Fluoro-2-methylpyridine factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.
